Inebilizumab
Inebilizumab
Inebilizumab (pronounced as in-uh-bil-iz-yoo-mab) is a monoclonal antibody designed for the treatment of neuromyelitis optica spectrum disorder (NMOSD).
Etymology
The name "Inebilizumab" is derived from the International Nonproprietary Names (INN), where "Ine-" refers to immune, "-bili-" refers to the target of the drug, which is B cells, and "-zumab" is a suffix used in names of humanized monoclonal antibodies.
Usage
Inebilizumab is used for the treatment of NMOSD, a rare, lifelong, and debilitating autoimmune disease of the central nervous system, affecting the optic nerves and spinal cord. Inebilizumab is specifically used in patients who are anti-aquaporin-4 (AQP4) antibody positive.
Mechanism of Action
Inebilizumab works by binding to the CD19 protein on the surface of B cells, a type of white blood cell, and induces their depletion. This reduces the autoimmune response and prevents damage to the nervous system.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Neuromyelitis optica spectrum disorder (NMOSD): A rare, lifelong, and debilitating autoimmune disease of the central nervous system.
- Aquaporin-4 (AQP4): A protein that forms a pore in the cell membrane and primarily functions to conduct water molecules in and out of the cell.
- CD19: A protein found on the surface of B cells, a type of white blood cell.
External links
- Medical encyclopedia article on Inebilizumab
- Wikipedia's article - Inebilizumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski